Abstract Type 2 diabetes (T2D) generally requires a combination of several pharmacological approaches to control hyperglycaemia. Combining a sodium-glucose cotransporter type 2 inhibitor (SGLT2I, also known as gliflozin) and a dipeptidyl peptidase-4 inhibitor (DPP-4I, also known as gliptin) appears to be an attractive strategy because of complementary modes of action. This narrative review analyzes the pharmacokinetics and clinical efficacy of different combined therapies with an SGLT2I (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin) and DPP-4I (linagliptin, saxagliptin, sitagliptin, teneligliptin). Drugdrug pharmacokinetic interaction studies do not show any significant changes in peak concentrations (C max ) and total exposure (area under the curve of plasma concentrations [AUC]) of either drug when they were administered together orally compared with corresponding values when each of them was absorbed alone. Two fixed-dose combinations (FDCs) are already available (dapagliflozin-saxagliptin, empagliflozin-linagliptin) and others are in development (ertugliflozin-sitagliptin). Preliminary results show bioequivalence of the two medications administered as FDC tablets when compared with coadministration of the individual tablets. Dual therapy is more potent than either monotherapy in patients treated with diet and exercise or already treated with metformin. SGLT2I and DPP-4I could be used as initial combination or in a stepwise approach. The additional glucose-lowering effect appears to be more marked when a gliflozin is added to a gliptin than when a gliptin is added to a gliflozin. Combining the two pharmacological options is safe and does not induce hypoglycaemia.
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Introduction
Combination therapy is recommended after failure of metformin monotherapy for the management of hyperglycaemia in type 2 diabetes (T2D). Various pharmacological approaches may be added to metformin as dual therapies or combined together as triple therapies, including sodiumglucose cotransporter type 2 inhibitors (SGLT2I) and dipeptidyl peptidase inhibitors (DPP-4Is) [1, 2] .
SGLT2Is (also known as gliflozins), which target the kidney and promote glucosuria, belong to the newest pharmacological class of glucose-lowering agents [3] . Both their efficacy and safety have recently been reviewed [4, 5] . In T2D patients with a history of cardiovascular disease, the demonstration of a remarkable reduction in cardiovascular and renal events with empagliflozin in the EMPA-REG OUTCOME trial [6, 7] raised huge interest among the medical community; [8] however, the underlying mechanisms of protection of empagliflozin remain unknown and controversial [9, 10] . SGLT2Is, by specifically targeting the kidney, inhibit glucose reabsorption at the proximal tubule and thereby promote glucosuria, an effect independent of insulin. By reducing hyperglycaemia, SGLT2Is dampen glucotoxicity, which indirectly results in an improvement of both b-cell function and peripheral insulin sensitivity [11] [12] [13] . However, treatment with SGLT2Is resulted in an increase in plasma glucagon concentrations, which was accompanied by a substantial increase in endogenous (hepatic) glucose production [11, 12] . Increased glucagon secretion has also been implicated in the occurrence of euglycaemic ketoacidosis episodes reported with SGLT2Is [14, 15] . Thus, the addition of a DPP-4I, which inhibits glucagon and stimulates insulin secretion, may have the potential to block the increase in endogenous glucose production and thereby enhance the glucose-lowering ability of SGLT2I while reducing the risk of ketoacidosis, although this remains to be proven. Beyond a glucose-lowering effect, SGLT2Is have some added value with reductions in body weight (including abdominal adiposity), blood pressure and serum uric acid, all markers considered as independent cardiovascular risk factors [3] . In the EMPA-REG OUTCOME trial, empagliflozin was associated not only with a remarkable reduction in cardiovascular and all-cause mortality in T2D patients with antecedents of cardiovascular disease [6, 9] but also with a marked reduction in the incidence rate of hospitalization for heart failure [16] . Because of their specific mode of action, some limitations exist in using SGLT2I in patients with renal impairment [17] . DPP-4Is (also known as gliptins) are increasingly used in the management of T2D as an alternative or add-on therapy to other glucose-lowering agents [18] . As oral incretin-based therapy, they offer an excellent safety profile, with no increased risk of hypoglycaemia, weight gain and cardiovascular events when compared with placebo [19] . DPP-4Is enhance postprandial insulin secretion and suppress glucagon secretion by preventing the degradation of endogenously released incretin hormones (glucagon-like peptide [GLP]-1 and glucose-dependent insulinotropic polypeptide [GIP]), two intestinal peptides whose concentrations physiologically increase after food intake. Of major interest, DPP-4Is stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner, thus reducing hyperglycaemia while minimizing hypoglycaemia [18] . Furthermore, they do not induce weight gain and have proven their cardiovascular safety in several large, prospective, cardiovascular outcome studies [19, 20] . A higher rate of hospitalization for heart failure with the DPP-4I saxagliptin was reported in the SAVOR-TIMI 53 trial [21] . Because this adverse event was not observed with sitagliptin in the TECOS trial [22] , it remains controversial whether it is specific to saxagliptin, whether it is only a chance effect, or whether it might be a class effect [23, 24] . Moreover, because of the marked reduction in the rate of hospitalization for heart failure with empagliflozin in the EMPA-REG OUTCOME trial [16] , one may speculate that adding an SGLT2I to a DPP-4I would be of potential interest with regard to the risk of heart failure in patients with T2D [25] . DPP-4Is keep good efficacy, together with a favourable safety profile, in patients with renal impairment, although the dose should be reduced according to the glomerular filtration rate (for most of the DPP-4Is, except for linagliptin, which is not excreted in the urine) in order to maintain similar total exposure as in subjects with normal renal function [26] . They may be used in patients with mild to moderate hepatic impairment but are contraindicated in patients with severe hepatic failure [27] . Detailed pharmacokinetic characteristics of available DPP-4Is have been reported in two previous papers [28, 29] .
DPP-4Is and SGLT2Is exert their glucose-lowering effects via different and complementary mechanisms [30, 31] . When one single pharmacological class does not reach the glycated haemoglobin (HbA1c) target as monotherapy, or even when added to metformin, a combination of a DPP-4I and an SGLT2I could be helpful in the management of patients with T2D [32] [33] [34] [35] . Fixed-dose combinations (FDCs) have recently been commercialized, which should facilitate therapy and improve compliance of patients with T2D [36, 37] .
We previously analysed drug-drug interactions (DDIs) with SGLT2Is; [38] however, at the time of this initial publication, no studies that have evaluated the combination of an SGLT2I with a DPP-4I were available. Numerous studies about this combined therapy have been published since that time. The main aims of this narrative review were (1) to analyze the pharmacokinetic characteristics and DDIs when an SGLT2I (dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin) is combined with a DPP-4I (saxagliptin, linagliptin, sitagliptin, teneligliptin); and (2) for each SGLT2I, to briefly describe the clinical efficacy of the combination with a DPP-4I in randomized controlled trials (RCTs), knowing that safety issues are reassuring and not different from the tolerance profile of each compound taken alone.
To identify relevant studies, an extensive literature search of the MEDLINE database was performed from January 2010 to November 2016, using the terms 'DPP-4I', 'alogliptin', 'linagliptin', 'saxagliptin', 'sitagliptin', 'teneligliptin', 'vildagliptin', 'SGLT2I', 'canagliflozin', 'dapagliflozin', 'empagliflozin', 'ertugliflozin', 'ipragliflozin', 'luseogliflozin', 'tofogliflozin', 'combined therapy' and 'FDC'. No language restrictions were imposed. Reference lists of original studies, other narrative reviews and previous systematic reviews were also carefully examined. Recent abstracts presented at the 2016 annual meetings of the American Diabetes Association and the European Association for the Study of Diabetes were also scrutinized to identify valuable data related to the topic of this review and not yet published as full papers. For pharmacokinetic studies, we only selected studies that analysed the combination of a SGLT2I and a DPP-4I as separate tablets or as FDCs, either in healthy volunteers or in patients with T2D. Studies devoted to only one pharmacological class, either SGLT2I [3, 39] or DPP-4I [28, 29] , have already been analysed in previous papers. For clinical studies, we only selected RCTs that reported the results of a combined therapy with an SGLT2I and a DPP-4I in patients with T2D, focusing on phase III trials of at least 24 weeks' duration and 100 subjects per arm (except for trials in Japanese subjects where smaller studies with 35-100 subjects per arm were also taken into account, in the absence of larger studies). Numerous studies evaluating either an SGLT2I [3, 40] or a DPP-4I [18, 41] separately have been discussed in previous papers and are not taken into account in the present review specifically devoted to SGLT2I-DPP-4I combined therapy. Finally, the website ClinicalTrials.-gov was explored to identify unpublished trials. This website shows numerous ongoing trials designed to (1) better understand the complementary mode of action of SGLT2Is and DPP-4Is; (2) obtain further pharmacokinetic information regarding combined therapy (DDIs, FDC bioequivalence); and (3) demonstrate both the efficacy and safety of diverse combinations in T2D patients receiving various background therapies, mostly dapagliflozin plus saxagliptin, empagliflozin plus linagliptin, ertugliflozin plus sitagliptin, and ipragliflozin plus sitagliptin. The huge number of these trials demonstrates a major interest for such new therapeutic approaches, but does not permit consideration of these unpublished studies in the present review, especially as no results are available yet.
Dapagliflozin Plus Saxagliptin
The potential therapeutic value of a combination therapy with saxagliptin and dapagliflozin for the treatment of T2D has recently been reviewed [42] and an FDC has been developed [43] .
Pharmacokinetics
The absolute oral bioavailability of dapagliflozin and saxagliptin was determined using simultaneous intravenous [14] C-microdose/therapeutic oral dosing in healthy volunteers [44] . The geometric mean point estimates for dapagliflozin and saxagliptin were 78% (90% confidence interval [CI] 73-83%) and 50% (95% CI 48-53%), respectively, and the arithmetic mean half-life values for the intravenous and oral doses were similar-12.2 ± 5.3 and 13.7 ± 3.4 h for dapagliflozin, and 7.5 ± 0.6 and 5.7 ± 0.4 h for saxagliptin, respectively. Furthermore, the plasma concentration-time terminal elimination phases for each route were parallel. Thus, this study demonstrated that intravenous microdosing has similar pharmacokinetics to therapeutic oral dosing [44] .
The bioequivalence of saxagliptin/dapagliflozin 2.5/ 5 mg and 5/10 mg FDC tablets, compared with coadministration of the individual tablets, was evaluated in an openlabel, randomized, single-dose, crossover study in 72 healthy subjects [43] . Saxagliptin/dapagliflozin 2.5/5 mg and 5/10 mg FDC tablets were bioequivalent to coadministration of the individual components in healthy subjects under fasted conditions, as shown by the comparison of maximum observed plasma concentrations (C max ) and area under the plasma concentration-time curves (AUC) ( Table 1) . Plasma dapagliflozin and saxagliptin concentrations decreased in a multiexponential way, and the dapagliflozin profiles were similar in the case of the administration of individual components separately or as an FDC. The mean dapagliflozin terminal half-life (t ) was approximately 13-16 h, while the mean saxagliptin t was approximately 5.4-7.3 h across all treatments. This study also found that food has no clinically meaningful effect on the overall bioavailability (total exposure) of saxagliptin/dapagliflozin FDC. Nevertheless, the median time to reach C max (t max ) for dapagliflozin was delayed from 1 to 3 h, and the C max of dapagliflozin was reduced by Single-dose DDI study [60] Canagliflozin 200 AUC area under the plasma concentration-time curve, AUC t AUC from time zero to time t, AUC s AUC during a dosage interval, AUC s,ss AUC during a dosage interval at steady state, AUC 72 AUC from time zero to 72 h, C max maximum observed plasma concentration, C max,ss C max at steady state, DDI drug-drug interaction, DPP-4I dipeptidyl peptidase-4 inhibitor, FDC fixed-dose combination, NA not applicable, SGLT2I sodium-glucose cotransporter type 2 inhibitor approximately 35-50% under fed conditions, compared with fasted conditions, for the FDC tablet. In contrast, the C max of saxagliptin was unaffected by food [43] . A single-dose, open-label, randomized, three-period, three-treatment crossover DDI study was conducted to evaluate differences in the pharmacokinetic properties of saxagliptin and dapagliflozin when coadministered [45] . Forty-two healthy subjects were allocated to receive saxagliptin 5 mg alone, dapagliflozin 10 mg alone, or saxagliptin 5 mg plus dapagliflozin 10 mg coadministered, with a washout period of at least 6 days between treatments. Dapagliflozin had no effect on the pharmacokinetic properties of saxagliptin, its major active metabolite 5-OH saxagliptin, or saxagliptin total active moiety. Conversely, saxagliptin had no effect on dapagliflozin pharmacokinetics as 90% CIs for C max and AUC from time zero to infinity (AUC inf ) for all comparisons were contained entirely within the 0.80-1.25 equivalence intervals (Table 1) . Thus, no pharmacokinetic interaction could be detected when saxagliptin and dapagliflozin were coadministered [45] .
Clinical Efficacy
Changes in plasma glucose, insulin, and glucagon in relation to glycaemic response after a liquid meal tolerance test were analysed during treatment with dual add-on of dapagliflozin plus saxagliptin to metformin extended release compared with dapagliflozin add-on alone or saxagliptin add-on alone in patients with T2D poorly controlled with metformin [46] . The combination of dapagliflozin plus saxagliptin provided additional reductions in glucose AUC from zero to 180 min (AUC 180 min ) and HbA1c, without the increase in plasma insulin seen with saxagliptin alone, and without the increase in plasma glucagon seen with dapagliflozin alone [46] . The absence of plasma insulin increase with the addition of saxagliptin may probably be explained by the concomitant reduction in hyperglycaemia, mainly due to the amount of glucose lost in the urine. Several clinical studies have shown that the addition of a DPP-4I to background therapy with an SGLT2I results in only a modest HbA1c reduction, approximately half of that observed with the addition of an SGLT2I to DPP-4I background therapy [30] . The fact that the DPP-4I blunts the increase in glucagon seen with the SGLT2I might contribute to reducing the risk of euglycaemic ketoacidosis reported with SGLT2Is, although this remains to be demonstrated [40] .
Adults with poorly controlled T2D receiving background metformin were randomized to dapagliflozin 10 mg/day plus saxagliptin 5 mg/day, dapagliflozin 10 mg/day and placebo, or saxagliptin 5 mg/day and placebo [47] . At week 24, greater improvements in glycaemic control were obtained with the triple therapy by the dual addition of dapagliflozin and saxagliptin than dual therapy with the addition of dapagliflozin or saxagliptin alone to background metformin monotherapy. A greater reduction in HbA1c was observed, leading to a higher proportion of patients reaching an HbA1c target \7% (53 mmol/mol) with the triple therapy ( Table 2) . Improvement in glucose control resulted from greater reductions in both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG). The difference in blood glucose control was greater when the triple therapy was compared with the dual therapy metformin plus saxagliptin than when compared with the dual therapy metformin plus dapagliflozin. The reduction in body weight was greater with the triple therapy than with the dual therapy metformin plus saxagliptin, but not with the dual therapy metformin plus dapagliflozin [47] .
In another RCT, treatment with dapagliflozin 10 mg add-on to saxagliptin 5 mg plus metformin resulted in a greater mean HbA1c reduction from baseline to week 24 than placebo added to saxagliptin 5 mg (-0.82 vs. -0.10%; p \ 0.0001) and a higher proportion of T2D patients reaching a target HbA1c\7% (53 mmol/mol; 38.0 vs. 12.4%; p \ 0.0001) ( Table 3 ) [48] . There were statistically significantly larger reductions (all p \ 0.0001) in the dapagliflozin add-on to saxagliptin plus metformin group compared with the placebo add-on to saxagliptin plus metformin group in FPG, 2-h PPG level (difference -36 mg/day; 95% CI -46.3 to -24.7), and body weight (Table 3 ) [48] .
When compared with the previous RCT, treatment with saxagliptin 5 mg add-on to dapagliflozin 10 mg plus metformin resulted in a less marked reduction in HbA1c (-0.51 vs. -0.16% with placebo), but the difference remained highly significant (p \ 0.0001) [49] . A larger proportion of patients achieved HbA1c \7% (53 mmol/mol) with saxagliptin add-on (35.3%) versus placebo add-on (23.1%) to dapagliflozin plus metformin (Table 4) ; however, reductions in FPG and 2-h PPG were similar between treatment arms [49] . Indirect comparison with findings of the previous trial [48] may suggest that the addition of dapagliflozin on top of a dual therapy metformin plus saxagliptin results in a greater improvement in glucose control than the addition of saxagliptin on top of a dual therapy metformin plus dapagliflozin [30] .
Empagliflozin Plus Linagliptin
The potential therapeutic value of a combination therapy with empagliflozin and linagliptin for the treatment of T2D has recently been reviewed [50, 51] , as well as the 
Pharmacokinetics
In an open-label, randomized, multiple-dose, crossover study, 16 healthy male subjects received empagliflozin 50 mg once daily for 5 days, both empagliflozin 50 mg once daily and linagliptin 5 mg once daily for 7 days, and linagliptin 5 mg once daily for 7 days [53] . Empagliflozin was rapidly absorbed, with a median t max at steady state (t max,ss ) of 1 h. Empagliflozin total exposure at steady state (AUC s,ss ) after oral administration of empagliflozin 50 mg was similar with or without linagliptin 5 mg, with respect to the standard bioequivalence acceptance range of 0.80-1.25. C max at steady state (C max,ss ) was approximately 12% lower when empagliflozin was administered with linagliptin than when administered alone, with a corresponding 90% CI of 0.79-0.99, which was slightly outside the bioequivalence acceptance range (Table 1) . However, this modest reduction in empagliflozin peak exposure when linagliptin was coadministered was not considered clinically meaningful. The median t max,ss was slightly longer when empagliflozin was administered with linagliptin (1.5 vs. 1 h). T values at steady state were similar when empagliflozin was administered alone (8.30 ± 11.4 h) or coadministered with linagliptin (8.44 ± 10.7 h). Linagliptin total exposure (AUC) and C max were unaffected by coadministration of empagliflozin ( Table 1 ). The median t max,ss for linagliptin was the same (1.5 h) with or without coadministration of empagliflozin. Consequently, these data support the coadministration of empagliflozin and linagliptin without dose adjustments [53] . An open-label, randomized, single-dose, crossover study was completed in August 2016 (ClinicalTrials.gov identifier: NCT02758171), the aim of which was to test the bioequivalence of an FDC tablet of empagliflozin/linagliptin compared with the free combination of empagliflozin tablet and linagliptin tablet in healthy male and female subjects under fasted conditions. The results have not yet been published.
Clinical Efficacy
A single-pill combination of empagliflozin and linagliptin was shown to produce clinical improvements in glycaemic control that were generally superior to the corresponding improvements seen with each individual component, either empagliflozin or linagliptin alone. The findings were consistent in two RCTs of up to 52 weeks' duration in patients with T2D treated with diet and exercise [54] or metformin monotherapy [55] . odds ratio, SGLT2I sodium-glucose cotransporter type 2 inhibitor, Tofo tofogluflozin T2D patients not receiving glucose-lowering medications for at least 12 weeks were randomized to receive empagliflozin 25 mg/linagliptin 5 mg, empagliflozin 10 mg/linagliptin 5 mg, empagliflozin 25 mg, empagliflozin 10 mg, or linagliptin 5 mg for 52 weeks [54] . Reductions in HbA1c at week 24 (primary endpoint) were significantly greater for empagliflozin 25 mg/linagliptin 5 mg compared with linagliptin 5 mg (p \ 0.001), but not compared with empagliflozin 25 mg, and were significantly greater for empagliflozin 10 mg/linagliptin 5 mg compared with linagliptin 5 mg and empagliflozin 10 mg individual components (p \ 0.001 for both). These changes translated into different proportions of patients with baseline HbA1c C7% who reached HbA1c \7% (53 mmol/mol) at week 24 ( Table 2 ). Similar differences in favour of the dual therapy were noticed for FPG levels ( Table 2) . Overall, the clinical efficacy was maintained at week 52 (data not shown) [54] .
To evaluate the efficacy of combinations of empagliflozin/linagliptin as second-line therapy, subjects with T2D inadequately controlled on metformin were randomized to a combination of empagliflozin 25 mg/linagliptin 5 mg, empagliflozin 10 mg/linagliptin 5 mg, empagliflozin 25 mg, empagliflozin 10 mg, or linagliptin 5 mg as add-on to metformin for 52 weeks [55] . At week 24 (primary endpoint), reductions in HbA1c with empagliflozin/linagliptin were superior to those with empagliflozin or linagliptin alone when added to metformin, and more subjects reached HbA1c \7% (53 mmol/mol) with the triple therapy compared with each dual therapy. The same trends were observed regarding reductions in FPG levels ( Table 2 ). The greater glucose-lowering efficacy of the triple therapy metformin/empagliflozin/linagliptin compared with each dual therapy (either metformin/empagliflozin or metformin/linagliptin) was maintained at week 52 [55] .
Finally, two phase III studies investigated the efficacy of linagliptin 5 mg versus placebo as add-on to empagliflozin 10 mg or empagliflozin 25 mg, respectively. Initially, T2D patients not well-controlled with metformin received openlabel empagliflozin 10 mg (study 1; n = 352) or empagliflozin 25 mg (study 2; n = 354) for 16 weeks [56] . Subsequently, patients with HbA1c between 7.0 and 10.5% were randomized to double-blind, double-dummy treatment with a single-pill combination of linagliptin 5 mg/ empagliflozin 10 mg (n = 126) or placebo ? empagliflozin 10 mg (n = 130) in study 1, and a single-pill combination of linagliptin 5 mg/empagliflozin 25 mg (n = 114) or placebo ? empagliflozin 25 mg (n = 112) in study 2. At week 24, linagliptin 5 mg significantly reduced HbA1c as add-on to empagliflozin 10 mg (from baseline placebo-subtracted reduction -0.32%; p = 0.0103) or 25 mg (placebo-subtracted reduction -0.47%; p \ 0.001) 
Canagliflozin Plus a Dipeptidyl Peptidase-Inhibitor
Canagliflozin is another SGLT2I commercialized in both the US and Europe [57] . However, the only available DDI pharmacokinetic study of canagliflozin with a DPP-4I relates to teneligliptin, a DPP-4I not available in these countries but available in Japan (trade name Tenelia 
Pharmacokinetics
Pharmacokinetic interactions between canagliflozin and teneligliptin were investigated in Japanese healthy adult men in an open-label, one-way, crossover study using canagliflozin (200 mg/day, dose used in Japan) and teneligliptin (40 mg/day) [60] . A single dose of object drug (either canagliflozin or teneligliptin) was administered on day 1 followed by washout. After a continuous administration of precipitant drug (days 1-9), both drugs were concomitantly administered on day 7. No changes in exposure (AUC from time zero to 72 h [AUC 72 ]) and C max were observed for canagliflozin plus teneligliptin versus each monotherapy (Table 1) . Thus, the results of this single-dose study showed no pharmacokinetic interaction between canagliflozin and teneligliptin [60] .
Clinical Efficacy
In the ongoing prospective cardiovascular outcome trial CANVAS, 316 of 4330 patients were taking a DPP-4I, mainly sitagliptin (75.6%) and vildagliptin (22.5%). The addition of canagliflozin provided significant placebosubtracted reductions in HbA1c in those patients taking DPP-4Is. At 18 weeks, the HbA1c reduction was greater with canagliflozin 300 mg (-0.75%, 95% CI -0.95 to -0.54) than with canagliflozin 100 mg (-0.56%, 95% CI -0.77 to -0.35) [61] . Significant placebo-subtracted reductions in body weight (-2.7 kg with canagliflozin 300 mg and -2.0 kg with canagliflozin 100 mg) and systolic blood pressure (-4.7 mmHg with both dosages) were also noted. Although the incidence of hypoglycaemia was numerically higher with canagliflozin versus placebo, nearly all events occurred in patients receiving background insulin therapy or sulphonylureas. In patients receiving background DPP-4Is, the add-on therapy with canagliflozin improved HbA1c, body weight and systolic blood pressure, without worsening the risk of hypoglycaemia, but at the expense of an increased incidence of known adverse events related to SGLT2Is, especially mycotic genital infections [61] .
Sodium-Glucose Cotransporter Type 2 Inhibitor Combined with Sitagliptin
Sitagliptin is the most widely used DPP-4I worldwide [62] . Thus, it is not surprising that it has been investigated in combination with almost all SGLT2Is, not only those available in Europe and the US but also several others commercialized in Japan.
Dapagliflozin Plus Sitagliptin

Pharmacokinetics
The study by Kasichayanula et al. assessed the potential for pharmacokinetic DDIs between dapagliflozin and different glucose-lowering agents, including sitagliptin, in healthy subjects [63] . In this open-label, randomized, crossover study, 18 subjects received a single-dose of sitagliptin 100 mg or sitagliptin 100 mg plus dapagliflozin 20 mg. The mean dapagliflozin plasma concentration versus time profile was similar with and without coadministration of sitagliptin. The pre-specified criteria to conclude a lack of interaction between dapagliflozin and sitagliptin were met for C max and AUC as the 90% CIs were within the no-effect interval of 0.8-1.25 (Table 5 ). The t max and t for dapagliflozin were also unaffected by coadministration of sitagliptin. The median (range) t max for dapagliflozin was 1.5 h (1.0-4.0) without and 1.7 h (1.0-6.0) with sitagliptin coadministration. Furthermore, the mean t values for dapagliflozin were 14.3 ± 10.1 h without and 15.9 ± 7.1 h with sitagliptin coadministration [63] . Similarly, no meaningful differences in C max and AUC were observed for sitagliptin in the presence of dapagliflozin as the 90% CIs were within the no-effect interval (Table 5) . Again, the t max and t for sitagliptin were unaffected by coadministration of dapagliflozin. The median t max for sitagliptin was 3.0 h (0.5-5.8) without dapagliflozin, and 4.0 h (1.5-8.0) with dapagliflozin [63] . The respective t values for sitagliptin were 14.2 ± 2.0 h and 14.4 ± 2.0 h in the absence and presence of dapagliflozin, respectively.
Clinical Efficacy
The RCT by Jabbour et al. assessed the efficacy and safety of dapagliflozin 10 mg (n = 225) versus placebo Table 5 Results of pharmacokinetic interactions in studies combining an SGLT2I (dapagliflozin, empagliflozin, ipragliflozin, tofogliflozin and ertugliflozin; no such specific study for canagliflozin) with sitagliptin, the most widely prescribed DPP-4I, used as reference AUC area under the plasma concentration-time curve, AUC t AUC from time zero to time t, AUC t,ss AUC from time zero to time t at steady state, AUC inf AUC from time zero to infinity, C max maximum observed plasma concentration, C max,ss C max at steady state, DPP-4I dipeptidyl peptidase-4 inhibitor, SGLT2I sodium-glucose cotransporter type 2 inhibitor (n = 226) as add-on therapy to sitagliptin 100 mg with or without metformin in patients with inadequately controlled T2D [64] . At 24 weeks, add-on treatment with dapagliflozin provided additional clinical benefit, with a significant reduction in HbA1c (-0.5 vs. 0% with placebo) and body weight (-2.1 vs. -0.3 kg) ( Table 3) . Dapagliflozin also decreased HbA1c significantly versus placebo when added to sitagliptin alone (placebo-subtracted -0.6%; p \ 0.0001) or to sitagliptin plus metformin dual therapy (placebo-subtracted -0.4%; p \ 0.0001). Glycaemic and body weight benefits observed at week 24 were maintained through week 48, and fewer patients receiving dapagliflozin were discontinued or rescued for failing to achieve glycaemic targets compared with placebo [64] .
Canagliflozin Plus Sitagliptin
Pharmacokinetics
The study by Kinoshita and Kondo tested the pharmacokinetic interactions between canagliflozin and teneligliptin (see Sect. 4.1) [60] , but to our knowledge no study specifically investigated DDIs between canagliflozin and sitagliptin.
Clinical Efficacy
Patients with T2D inadequately controlled on metformin C1500 mg/day and sitagliptin 100 mg randomly and blindly received canagliflozin 100 mg or placebo [65] . After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg in 85.4% of patients. At week 26, canagliflozin (pooled 100 and 300 mg doses) demonstrated superiority in HbA1c reduction versus placebo (-0.91 vs. -0.01%; p \ 0.001). Canagliflozin provided significant reductions in FPG, body weight and systolic blood pressure compared with placebo (p \ 0.001) ( Table 3) . A 52-week, open-label study performed in Japanese patients with T2D evaluated the efficacy and safety of adding canagliflozin 100 or 200 mg once daily (doses used in Japan) to different background glucose-lowering therapies, including DPP-4Is (sitagliptin, vildagliptin or alogliptin) [66] . The baseline to endpoint change in HbA1c was -1.04% with canagliflozin 100 mg (n = 71) and -1.26% with canagliflozin 200 mg (n = 74) in patients already treated with DPP-4Is (the proportion of patients receiving sitagliptin is unknown) ( Table 3 ). These reductions were almost similar or slightly greater when compared with other subgroups receiving non-DPP-4I background glucose-lowering therapies. The addition of canagliflozin to a DPP-4I was also associated with significant reductions in FPG, body weight and systolic blood pressure. As expected from the properties of the combination drugs, the incidence of hypoglycaemia was much lower in patients treated with DPP-4Is than in those treated with a sulphonylurea [66] .
Empagliflozin Plus Sitagliptin
Pharmacokinetics
An open-label, randomized, multiple-dose (5 days), crossover study with three treatments and two treatment sequences investigated the potential DDIs between empagliflozin and sitagliptin in 16 healthy male volunteers [67] . Coadministration of sitagliptin 100 mg with empagliflozin 50 mg did not have a clinically relevant effect on the AUC s,ss or C max,ss of the analyte in plasma at steady state over a uniform dosing interval tau of empagliflozin (Table 5) . Similarly, coadministration of empagliflozin 50 mg with sitagliptin 100 mg did not have a clinically meaningful effect on the AUC s,ss or C max,ss of sitagliptin (Table 5 ). These results indicate that empagliflozin and sitagliptin can be coadministered without dose adjustments [67] .
Clinical Efficacy
In the EMPA-REG OUTCOME trial, 11.3% of patients receiving empagliflozin were receiving background therapy containing a DPP-4I (529 of a total of 4687 subjects) [6] . However, the proportion of patients receiving sitagliptin was not mentioned and no specific subanalysis was performed in this subgroup of T2D patients.
Ipragliflozin Plus Sitagliptin
Pharmacokinetics
The clinical pharmacokinetics and pharmacodynamics of the novel SGLT2I ipragliflozin, which has gained approval for clinical use in T2D in Japan, have been reviewed [68] . To investigate the effect of ipragliflozin on the pharmacokinetics of sitagliptin and vice versa, ipragliflozin 150 mg and sitagliptin 100 mg were administered alone or in combination in two cohorts of 32 healthy subjects [69] . Multiple doses of ipragliflozin did not change the AUC inf and C max of a single dose of sitagliptin: geometric mean ratio (GMR) and 90% CI for AUC inf and C max , with and without ipragliflozin, were within the predefined range of 80-125% (Table 5) . Similarly, multiple doses of sitagliptin did not change the pharmacokinetics of a single dose of ipragliflozin (Table 5) . Thus, no dose adjustments are likely to be required when ipragliflozin is administered in combination with sitagliptin in patients with T2D [69] .
Clinical Efficacy
Phase III studies assessing the safety and efficacy of either the addition of ipragliflozin once daily to sitagliptin background therapy (ClinicalTrials.gov identifier: NCT02577003), or the addition of sitagliptin once daily to ipragliflozin background therapy (ClinicalTrials.gov identifier: NCT02577016) in Japanese participants with T2D and inadequate glycaemic control receiving lifestyle and pharmacological monotherapy are ongoing. The primary hypothesis for these studies is that the addition of a second active drug compared with placebo provides greater reduction in HbA1c, as assessed by change from baseline at week 24, as has already been shown for the combinations saxagliptin-dapagliflozin [47] [48] [49] and linagliptin-empagliflozin [54, 55] .
Tofogliflozin Plus Sitagliptin
Pharmacokinetics
Tofogliflozin (Apleway Ò , Deberza Ò ) has been developed by Chugai Pharmaceutical for the treatment of T2D, and a marketing authorization application was filed in Japan in 2013 by licensees Sanofi K. K. and Kowa. Tofogliflozin has received its first global approval for this indication in Japan as either monotherapy or in combination with other antihyperglycaemic agents [70] .
The effects of sitagliptin 100 mg on the pharmacokinetics and pharmacodynamics of tofogliflozin 40 mg, and the effects of tofogliflozin 40 mg on the pharmacokinetics of sitagliptin 100 mg, were investigated in 18 healthy male volunteers [71] . A single dose of tofogliflozin had no or little effect on C max and exposure (AUC) of sitagliptin, and a single dose of sitagliptin had no or little effect on C max and AUC of tofogliflozin (Table 5) [71].
Clinical Efficacy
To evaluate the long-term efficacy of tofogliflozin, Japanese patients with T2D not well-controlled with another oral monotherapy were randomly assigned to receive oral tofogliflozin 20 or 40 mg once daily in an open-label trial lasting 52 weeks [72] . In the subgroup receiving background therapy with a DPP-4I (including sitagliptin), a significant reduction in HbA1c was noticed at 52 weeks: -0.78 ± 0.88% with the 20 mg dose (n = 32) and -0.93 ± 0.86% with the 40 mg dose (n = 60; both p \ 0.0001) ( Table 3 ). In the meantime, body weight was reduced by -2.69 ± 2.81 kg and -2.50 ± 1.86 kg, respectively (p \ 0.0001). Tofogliflozin also reduced waist circumference and lowered systolic/diastolic blood pressure [72] .
Luseogliflozin Plus Sitagliptin
Pharmacokinetics
Luseogliflozin (Lusefi
Ò
) is an oral SGLT2I developed by Taisho Pharmaceutical Co. Ltd for the treatment of Japanese patients with T2D [73] . A dedicated study investigated the potential DDIs between luseogliflozin 5 mg and sitagliptin 50 mg (dose used in Japan) in 12 healthy Japanese males [74] . When administered in combination with sitagliptin, the GMRs and 90% CIs for C max , AUC 24 , and AUC inf of luseogliflozin were within the reference range (Table 5) . Similarly, when sitagliptin was administered with luseogliflozin, the GMRs and 90% CIs for C max , AUC 24 , and AUC inf of sitagliptin were within the reference range for bioequivalence (Table 5 ).
Clinical Efficacy
An open-label trial investigated the efficacy of luseogliflozin added to existing oral antidiabetic drugs, including DPP-4Is, in Japanese patients with T2D inadequately controlled with monotherapy [75] . At week 52, luseogliflozin 2.5 mg added to a DPP-4I (including sitagliptin) in 103 patients resulted in a significant reduction in HbA1c (-0.52%; p \ 0.001), without increasing the risk of hypoglycaemia. Similarly, the decrease in FPG and body weight from baseline at week 52 in the subgroup receiving background therapy with DPP-4Is averaged -18.5 mg/dL and -1.96 kg, respectively (p \ 0.001 for both) (Table 3) [75].
Ertugliflozin Plus Sitagliptin
Pharmacokinetics
Ertugliflozin is a new orally active SGLT2I that is currently in codevelopment between Pfizer and Merck. The disposition of ertugliflozin (PF-04971729) was studied after a single 25 mg oral dose of [ 14 C]-ertugliflozin administered to healthy subjects [76] . The absorption of ertugliflozin was rapid, with a t max averaging 1.0 h. The total administered radioactivity excreted in feces and urine was 40.9 and 50.2%, respectively. Unchanged ertugliflozin collectively accounted for approximately 35% of the dose, suggestive of moderate metabolic elimination. The principal biotransformation pathway involved glucuronidation, whereas a minor metabolic fate involved oxidation by cytochrome P450. Overall, these data showed that the drug is well absorbed and eliminated largely via glucuronidation [76] .
In an open-label, randomized, three-period, single-dose, crossover study, 12 fasted healthy subjects received ertugliflozin 15 mg, sitagliptin 100 mg and ertugliflozin plus sitagliptin [77] . Ertugliflozin did not have any impact on the AUC inf or C max of sitagliptin as the 90% CIs for the GMRs were within 80 and 125%. Similarly, coadministration of sitagliptin with ertugliflozin had no effect on either the AUC inf or C max of ertugliflozin based on bioequivalence boundaries (Table 5 ). The lack of pharmacokinetic interaction demonstrates that ertugliflozin can be coadministered with sitagliptin without any need for dose adjustment [77] .
Clinical Efficacy
In a large RCT whose preliminary results were recently presented as congress abstracts, [78, 79] 1233 T2D patients who were inadequately controlled on metformin alone (C1500 mg/day) were randomized to one of five treatment groups in a 1:1:1:1:1 ratio: coadministration of ertugliflozin 5 mg with sitagliptin 100 mg; coadministration of ertugliflozin 15 mg with sitagliptin 100 mg; ertugliflozin 5 mg; ertugliflozin 15 mg; or sitagliptin 100 mg (VERTIS Factorial trial: ClinicalTrials.gov identifier: NCT02099110). The coadministration of ertugliflozin and sitagliptin improved blood glucose control, assessed by a significantly greater reduction in HbA1c at 26 weeks (primary endpoint) and the secondary endpoint of achieving an HbA1c goal of \7.0% (53 mmol/mol) ( Table 2 ). Furthermore, the study also showed that the combined therapy was significantly more effective than ertugliflozin or sitagliptin alone in reducing FPG, and significantly more effective in reducing body weight and systolic blood pressure compared with sitagliptin alone (but not ertugliflozin alone), all being secondary endpoints [78, 79] .
In a double-blind, randomized, phase III trial, T2D patients with HbA1c 7.0-10.5% receiving stable metformin C1500 mg/day and sitagliptin 100 mg/day were randomized to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo (VERTIS SITA2 trial: ClinicalTrials.gov identifier: NCT02036515; congress abstract only) [80] . After 26 weeks, ertugliflozin 5 and 15 mg were significantly more effective than placebo in reducing HbA1c, FPG, body weight and systolic blood pressure, and a significantly greater proportion of subjects reached the target of HbA1c \7.0% (Table 3) .
Conclusions
The combination of an SGLT2I and DPP-4I is an attractive therapeutic strategy because the complementary modes of action of the two medications contribute to improve blood glucose control in patients with T2D, without deteriorating the safety/tolerance profile of each compound. DDI studies between different DPP-4Is and SGLT2Is showed no significant changes in total exposure and C max , as well as in other classical PK parameters (t max and t ). Clinical trials showed that the combination of an SGLT2I and DPP-4I is effective and safe in patients with T2D treated with diet alone or metformin. FDC formulations combining saxagliptin plus dapagliflozin and linagliptin plus empagliflozin are already commercialized and other combinations are currently investigated for the management of T2D. In the absence of head-to-head trials comparing different DPP-4I-SGLT2I combinations, it is currently impossible to decide if one combination is superior to another for the management of T2D. Although the precise positioning of a DPP-4I-SGLT2I combination should be better delineated by further studies, this approach appears to be a new option for the management of patients with T2D, with a good efficacy/safety ratio. However, because of the higher cost of this combination, careful pharmacoeconomic evaluation would be of major interest.
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